Predicting memapsin 2 (β-secretase) hydrolytic activity

Xiaoman Li1, Huang Bo, Xuejun C Zhang

  • 1Protein Studies Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.

Insights

Memapsin 2 (BACE1) enzyme activity was predicted using a novel algorithm based on substrate-binding cleft preferences. This algorithm accurately forecasts enzyme efficiency and identifies new therapeutic targets for Alzheimer's disease.

Area of Science:

  • Biochemistry
  • Enzymology
  • Neuroscience

Background:

  • Memapsin 2 (BACE1) cleaves amyloid precursor protein (APP), producing β-amyloid, a key factor in Alzheimer's disease (AD).
  • BACE1 is a primary therapeutic target for AD inhibitor drugs due to its role in β-amyloid production.

Purpose of the Study:

  • To determine the hydrolytic preference of memapsin 2 across its 12 substrate-binding subsites.
  • To develop a predictive algorithm for memapsin 2 substrate hydrolytic efficiency.
  • To identify modified APP variants with potentially higher BACE1 cleavage rates.

Main Methods:

  • Determined relative k(cat)/K(M) (preference constant) for all 12 memapsin 2 subsites.
  • Developed a predictive algorithm using substrate sequences and experimentally determined preference constants.
  • Validated the algorithm against 12 known memapsin 2 protein substrates.
  • Analyzed crystal structure B-factors of bound transition-state analogs.

Main Results:

  • Established a predictive algorithm with an excellent correlation coefficient of 0.97 between predicted and experimental preference constants.
  • Identified six key subsites (P(4) to P(2)') that primarily determine memapsin 2 hydrolytic preference.
  • Predicted that an APP variant (APP(IDF)) with specific amino acid substitutions would exhibit the highest hydrolytic rate.

Conclusions:

  • The developed algorithm accurately predicts memapsin 2 substrate cleavage efficiency.
  • The P(4) to P(2)' subsites are critical for memapsin 2 substrate recognition and hydrolysis.
  • The designed APP(IDF) variant shows promise for use in AD research models, potentially enhancing β-amyloid production studies.

Related Concept Videos